Starpharma DEP - Docetaxel
From DEP® Drug Delivery
-
Most popular related searches
Details
The advantages* of DEP® docetaxel include:
- Reduction in neutropenia
- Tumour-targeting (~70x more); improved efficacy
- No steroid pre-treatment
- Improved pharmacokinetics
Clinical studies have demonstrated reduction in important side effects with DEP® including bone marrow toxicity, anaphylaxis, oedema, and hair-loss.
DEP® docetaxel has patent filings to 2032 (plus up to an additional ~5 years).
*Multiple preclinical studies have established improved efficacy, survival, and safety with DEP® with many different drugs.
Therapeutic Potential and Benefits
Superiority to docetaxel/Taxotere® alone across multiple cancer types
In xenograft studies DEP® docetaxel demonstrated a significant enhancement of anticancer effect when compared to docetaxel/Taxotere® alone. Furthermore, in the study 60% of animals treated with DEP® docetaxel had no evidence of tumours at 94 days - whereas 100% of the docetaxel treated mice showed significant tumour re-growth or recurrence at the same time point.
Customer reviews
No reviews were found for Starpharma DEP - Docetaxel. Be the first to review!